key: cord-1022230-j0ad9cpn
authors: Peng, Lei; Park, Jonathan J.; Fang, Zhenhao; Zhou, Xiaoyu; Dong, Matthew B.; Xiong, Qiancheng; Lin, Chenxiang; Chen, Sidi
title: Systems immune profiling of variant-specific vaccination against SARS-CoV-2
date: 2021-12-03
journal: bioRxiv
DOI: 10.1101/2021.12.02.471028
sha: b28c4fdd7198f7caf7b8389a1b9149beb909bcb7
doc_id: 1022230
cord_uid: j0ad9cpn

Lipid-nanoparticle(LNP)-mRNA vaccines offer protection against COVID-19. However, multiple variant lineages caused widespread breakthrough infections. There is no report on variant-specific vaccines to date. Here, we generated LNP-mRNAs specifically encoding wildtype, B.1.351 and B.1.617 SARS-CoV-2 spikes, and systematically studied their immune responses in animal models. All three LNP-mRNAs induced potent antibody responses in mice. However, WT-LNP-mRNA vaccination showed reduced neutralization against B.1.351 and B.1.617; and B.1.617-specific vaccination showed differential neutralization. All three vaccine candidates elicited antigen-specific CD8 and CD4 T cell responses. Single cell transcriptomics of B.1.351-LNP-mRNA and B.1.617-LNP-mRNA vaccinated animals revealed a systematic landscape of immune cell populations and global gene expression. Variant-specific vaccination induced a systemic increase in reactive CD8 T cell population, with a strong signature of transcriptional and translational machineries in lymphocytes. BCR-seq and TCR-seq unveiled repertoire diversity and clonal expansions in vaccinated animals. These data provide direct systems immune profiling of variant-specific LNP-mRNA vaccination in vivo.

It has been widely hypothesized that the next-generation of COVID-19 vaccines can be designed to directly 1 target these variants ("variant-specific vaccines"). However, to date, there has been no literature report on any 2 approved or clinical stage variant-specific vaccine. Moreover, the immune responses, specificity, cross-3 reactivity, and host cell gene expression landscapes upon vaccination have to be rigorously tested for such 4 variant-specific vaccines to be developed. To directly assess the immunogenicity of potential variant-specific 5 SARS-CoV-2 vaccination, we generated LNP-mRNA vaccine candidates that encode the B.1.351 and B.1.617 6 spikes, along with the WT spike. With these variant-specific LNP-mRNAs, we characterized the immune 7 responses they induce in animals against homologous (cognate) and heterologous spike antigens and SARS-8

CoV-2 pseudoviruses. To better understand the systematic immune responses induced by variant-specific 9 SARS-CoV-2 spike mRNA-LNP vaccination, we analyzed the combined single-cell transcriptomes and preserve integrity of spike S1 and S2 subunits (Figure 1a-1b have mean diameters of 80.7 ± 6.9nm, 66.4 ± 5.3 nm and 72.2 ± 5.8 nm with a monodispersed size distribution 24 as determined by DLS and polydispersity indices of 0.08, 0.13 and 0.08, respectively ( Figure S 1c-1d) . The 25 immunogenicity of the LNP-mRNA was assessed in C57BL/6Ncr mice by two intramuscular injections (doses) 26 of 1 µg or 10 µg LNP-encapsulated mRNA, separated by 3 weeks (prime and boost, respectively) (Figure 1c) . 27 Serum samples were collected two weeks after the prime and boost, and then subjected to ELISA and 28 neutralization assays to evaluate the antibody response. These mice were sacrificed 40 days post vaccination, 29 and the spleen, lymph nodes and blood cells were collected for downstream assays, including single cell 30 transcriptomics sequencing (scRNA-seq), bulk and single cell BCR sequencing (BCR-seq) and TCR 31 sequencing (TCR-seq), as well as flow cytometry. All procedures were standardized across all groups. 32 Immune responses induced by WT-LNP-mRNA vaccination in mice 1 WT-LNP-mRNA induced dose-dependent binding antibody responses against spike ECD and RBD of SARS-2 CoV-2 WT, B.1.351 and B.1.617 variants after prime and boost (Figure 1d-e) . Compared to the post-prime 3 immune response, orders of magnitudes increase in immune response were observed after the boost injection, 4

suggesting that the second dose significantly boosted B cell immunity to SARS-CoV-2 antigen (Figure 1d-e) . 5

Using a pseudovirus neutralization assay that has been widely reported to be consistent with authentic virus 6 results (Chen et al., 2021; Schmidt et al., 2020a) , the serum samples from mice receiving WT-LNP-mRNA 7 vaccination also showed potent neutralization activity against all three variants, again with a strong prime-8 boost effect (Figure 1f) . However, the neutralization ability of WT-LNP-mRNA vaccinated sera was found to 9 be several fold lower against either B.1.351 or B.1.617 as compared to the cognate WT pseudovirus (Figure  10 The strong boost effect in ELISA was also observed for these two variant-specific LNP-mRNAs ( boost response reported in ELISA (Figure 2c-2d) . The initial level of neutralization was at 10 2 -10 3 level of 7 reciprocal IC50 after priming for most groups (Figure 2c-2d) . Consistent with findings in ELISA, an 8 approximately two orders of magnitude increase in neutralization titer by boost was observed across all groups 9

(for both vaccine candidates and for all three pseudovirus types) in the low dose (1 µg) setting, and there was 10 an approximately one order of magnitude increase in the high dose (10 µg) setting (Figure 2c-2d across all vaccination groups, the neutralization activity strongly correlates with binding intensity for ECD 19 binding (Figure 2e) , which also holds true for RBD binding (Figure S 1h) . Similarly, to evaluate the T cell response to the spike peptides, the splenocytes were isolated from mouse 24 spleens 40 days post vaccination and the antigen-specific CD4 + and CD8 + T cell responses to S peptide pools 25 were determined by intracellular cytokine staining ( Figure S 2e-g) . Positive control PMA/ionomycin treatment 26 group and negative control no peptide group were both validated ( Figure S 2f-g) . Both B.1.617-LNP-mRNA 27 and B.1.351-LNP-mRNA, at low and high doses, induced potent reactive CD8 + T cell responses in terms of 28 cellular production of IFN-γ, TNF-a, and IL-2 (Figure 3a-3c) . Both LNP-mRNAs at both doses also induced 29 reactive CD4 + T cells that produce IFN-γ, but only minimally for TNF-a, and had no effect on IL-2, IL-4 or To examine the transcriptomic changes in the B and T cell sub-populations upon vaccination, we performed 26 differential expression (DE) analysis in the matched sub-populations between PBS and B.1.351-LNP-mRNA, 27 or B.1.617-LNP-mRNA, groups. Vaccination caused differential expression of genes in host B cells, CD4 T 28 cells and CD8 T cells (Figure 5e-g; Figures S 5) . The differentially expressed genes intersect with genes in 29 B cell activation, immune effector, and immune response genes, such as Lyn, Cd22 and Btla (Figure S 5a-b) . 30

The differentially expressed genes in CD4 and CD8 T cells also intersect with genes in T cell activation, 31 immune effector, and immune response genes, such as Cd40lg, Perforin/Prf1, Dhx36, Ddx17, Ddx21, Ccl5, represent transcription and translation machineries, which is consistent between B. It has been speculated that the waning immunity from early vaccination and emergence of more virulent SARS-5

CoV-2 variants may lead to reduction in vaccine protection and increase of breakthrough infections(Callaway, To detect surface-protein expression, the cells were stained with 10 µg/mL ACE2-Fc chimera (Genescript, 6 Z03484) in MACS buffer for 30 min on ice. Thereafter, cells were washed twice in MACS buffer and incubated 7 with PE-anti-human FC antibody (Biolegend, M1310G05) in MACS buffer for 30 min on ice. Live/Dead aqua 8 fixable stain (Invitrogen) were used to assess viability. Data acquisition was performed on BD FACSAria II 9

Cell Sorter (BD). Analysis was performed using FlowJo software. 18

A standard two-dose schedule given 21 days apart was adopted (Polack et al., 2020). 1 µg or 10 µg LNP-20 mRNA were diluted in 1X PBS and inoculated into mice intramuscularly for prime and boost. Control mice 21 received PBS. Two weeks post-prime (day14) and two weeks post-boost (day 35), sera were collected from 22 experimental mice and utilized for following ELISA and neutralization assay of pseudovirus. Forty days (day 23 40) after prime, mice were euthanized for endpoint data collection. Splenocytes were collected for T cell 24 stimulation and cytokine analysis, and single cell profiling. Lymphocytes were separately collected from 25 mouse blood, spleen and draining lymph nodes and applied for Bulk BCR and TCR profiling. 26 27

For every mouse treated with either LNP-mRNA or PBS. Blood, spleens and draining lymph nodes were 29 separately collected. Spleen and lymph node were homogenized gently and filtered with a 100 µm cell strainer 30 (BD Falcon, Heidelberg, Germany). The cell suspension was centrifuged for 5 min with 400 g at 4 °C. adding 10 mL PBS containing 2% FBS to restore iso-osmolarity. The single-cell suspensions were filtered 1 through a 40 µm cell strainer (BD Falcon, Heidelberg, Germany). PBST at room temperature for one hour. Plasma was serially diluted twofold or fourfold starting at a 1:2000 1 dilution. Samples were added to the coated plates and incubate at room temperature for one hour, followed by 2 washes with PBST five times. Anti-mouse secondary antibody was diluted to 1:2500 in blocking buffer and 3 incubated at room temperature for one hour. Plates were washed five times and developed with 4 tetramethylbenzidine substrate (Biolegend, 421101). The reaction was stopped with 1 M phosphoric acid, and 5 OD at 450 nm was determined by multimode microplate reader (PerkinElmer EnVision 2105). The binding 6 response (OD450) were plotted against the dilution factor in log10 scale to display the dilution-dependent 7 response. The area under curve of the dilution-dependent response (Log10 AUC) was calculated to evaluate 8 the potency of the serum antibody binding to spike antigens. supplied with 5% CO2. Then 100 µL of the mixtures were added into 96-well plates with 293T-hACE2 cells.

inhibitory concentration (IC50) was calculated with a four-parameter logistic regression using GraphPad Prism 1 (GraphPad Software Inc.). 2 3 Bulk BCR and TCR sequencing 4

Lymphocytes from blood, draining lymph node, spleen of each mRNA-LNP vaccinated and control mice were 5 collected as described above for mouse immunization and sample collection. mRNA of lymphocytes from 6 three tissues were extracted using a commercial RNeasy® Plus Mini Kit (Qiagen). Following bulk BCR and 7 TCR are prepared using SMARTer Mouse BCR IgG H/K/L Profiling Kit and SMARTer Mouse TCR a/b 8 profiling kit separately (Takara). Based on the extracted mRNA amount of each sample, the input RNA 9 amounts for bulk BCR libraries were as follows: lymphocytes from blood (100 ng), lymphocytes from lymph 10 node (1000 ng), and lymphocytes from spleen (1000 ng). The input RNA amounts for bulk TCR libraries were 11 as follows: lymphocytes from blood (100 ng), lymphocytes from lymph node (500 ng), and lymphocytes from 12 spleen (500 ng). All procedures followed the standard protocol of the manufacture. The pooled library was 13 sequenced using MiSeq (Illumina) with 2*300 read length. 14 15

Raw fastq files from bulk BCR and TCR sequencing were processed by MiXCR v2.1.5 to clonotypes. Paired-17 end reads were merged and aligned to reference genes for homo sapiens species using the function: mixcr align 18 -s hs, Clones were assembled using the mixcr assemble function, then exported for specific chains (TRB, TRA,  19 IGH, IGL, IGK) using the mixcr exportClones function. TCR-seq and BCR-seq data was subsequently 20 analyzed using the immunarch v0.6.6 R package for clonality analyses and calculating diversity metrics such 21 as the Chao1 estimator and Gini-Simpson index. 22

Splenocytes were collected from mRNA-LNP vaccinated and control mice were collected as described above 25

for mouse immunization and sample collection, and normalized to 1000 cells/µL. Standard volumes of cell 26 suspension were loaded to achieve targeted cell recovery to 10000 cells. The samples were subjected to 14 27 cycles of cDNA amplification. Following this, gene expression (GEX), TCR-enriched and BCR-enriched 28 libraries were prepared according to the manufacturer's protocol (10x Genomics). All libraries were sequenced 29 using a NovaSeq 6000 (Illumina) with 2*150 read length. 30

Both standard established pipelines and custom scripts were used for processing and analyzing single cell GEX 1 data. Illumina sequencing data was processed using the Cellranger v5.0.1 (10x Genomics) pipeline and aligned 2 to the mm10 reference. Cellranger outputs were then processed and analyzed using standard Seurat v. 4.0.2 3 workflow, including log normalization with scale factor 10,000, scaling and centering, principal components 4 analyses, nearest-neighbor graph construction, clustering with the Louvain algorithm, uniform manifold 5 approximation and projection (UMAP), differential gene expression, and generation of various visualizations. 6

The following parameters were used: for the FindNeighbors function, dims = 1:10; for FindClusters, resolution 7 = 0.6; for RunUMAP, dims = 1:10; for FindAllMarkers, only.pos = TRUE, min.pct = 0.25, logfc.threshold = 8 0.25. 9

10 Assignment of immune cell type identity to clusters was performed manually based on expression of cell type 11 specific markers. Custom scripts were used for cell proportion calculations and condition-specific analyses 12 and statistics (e.g. Wilcoxon rank sum test). While cluster 5 cells were annotated as "CD8 T / NKT cell" as it 13 was a mixed population, these cells were merged with the "CD8 T cell" annotation for proportion calculations 14 after cells with greater than 1 expression for any of the following markers were removed: Klrb1, Klra6, Klra1, 15

Zbtb16. Differential gene expression between conditions for various cell types were performed by the 16 In this figure, panels e and g: 10 Each dot represents data from one mouse. 11

The high dose (n = 3 each) and low dose (n = 3 each) groups for each vaccine were merged (n = 6 total) in 12 single cell data analysis, same thereafter. 13

Statistical significance labels: n.s., not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001 14 Neutralization log10 IC50 

Effectiveness of the

BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections

COVID vaccine boosters: the most important questions

Heavily mutated Omicron variant puts scientists on alert

Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness 20 of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France

Addendum: A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat 2 Microbiol 6

How the Delta variant achieves its ultrafast spread

Measuring SARS-CoV-2 neutralizing antibody activity using 6 pseudotyped and chimeric viruses

Measuring SARS-CoV-2 neutralizing antibody activity using 9 pseudotyped and chimeric viruses

Next-Generation Sequencing of T and B Cell Receptor Repertoires

SARS-CoV-2 variants of concern are 14 emerging in India

Six Month Safety and 20 Efficacy of the BNT162b2 mRNA COVID-19 Vaccine

WT ECD **** **** **** **** **** **** **** **** ns *** *** *** **